Cargando…
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. SUMMARY: In recent years, immune checkpoint inhibitors have made a breakthrough in the system...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801175/ https://www.ncbi.nlm.nih.gov/pubmed/36589726 http://dx.doi.org/10.1159/000526038 |